28 research outputs found
Dynamics of the shrub-tree component of an alluvial gallery forest on the Poços de Caldas Plateau, MG State, Brazil
A dinâmica do componente arbustivo-arbóreo foi investigada em uma floresta de galeria aluvial em Poços de Caldas, Minas Gerais, entre 1998 e 2005. Os objetivos principais foram: investigar se as taxas de dinâmica das florestas de galeria aluviais são inferiores a outras formações florestais ripárias tropicais e, se as inundações periódicas geram variação espacial na dinâmica no sentido Rio-Borda. A amostragem foi composta de 101 parcelas de 10 × 10 m, distribuídas em 5 blocos ao longo de, aproximadamente, 8 km da floresta do Rio das Antas. Cada bloco foi dividido em 3 setores (Rio, Interior e Borda). Comparativamente a outras florestas tropicais ripárias, a floresta em estudo apresentou taxas de dinâmica mais lentas. A Borda foi mais dinâmica que os outros setores, provavelmente devido à maior incidência luminosa, propiciando ambiente adequado às espécies de ciclo de vida curto.The dynamics of the shrub-tree component was investigated in an alluvial gallery forest in Poços de Caldas, Minas Gerais, from 1998 to 2005. The main objective of this study was to verify if the rates of the dynamics of the alluvial gallery forests are less than other tropical riparian forest formations. Seasonal flooding was also studied to see if it generates a spatial variation in the dynamics of going from the stream side towards the forest border. The sample consisted of 101, 10×10-meter plots that were distributed in five blocks extending approximately 8 km along the Antas River's forest. Each block was divided into three sectors (stream side, forest interior, and forest edge). Compared with other tropical forests, especially the riparian ones, this forest showed lower rates in terms of structural alterations. The forest edge is more dynamic, mainly due to the greater amount of sunlight, which supplies an adequate environment for species with a short life cycle
Manifestações iniciais nos pacientes com diagnóstico de Lúpus Eritematoso Sistêmico em acompanhamento no ambulatório de reumatologia do Hospital de Clínicas de Porto Alegre (HCPA)
Estimação de parâmetros genéticos de ovinos da raça Santa Inês utilizando modelos uni e bicaracterística
Dinâmica da comunidade arbórea em um fragmento de floresta estacional semidecidual montana em Lavras, Minas Gerais, em diferentes classes de solos
Escalas concorrentes para a mensuraçãoda qualidade percebida: uma comparação entre a Servqual e a RSQ
Cinnamic acid induces apoptotic cell death and cytoskeleton disruption in human melanoma cells
Avaliação do efeito do estresse hídrico no crescimento de cultivares de cana-de-açúcar usando um sistema automático de fertirrigação
Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.
Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.
Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049